zimberelimab

Overview

Zimberelimab is an investigational monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, a key immune checkpoint molecule expressed on activated T cells. By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, zimberelimab relieves inhibitory signaling that tumor cells exploit to suppress antitumor immune responses. As a member of the anti-PD-1 class of immunotherapeutic agents, zimberelimab functions by restoring the cytotoxic activity of tumor-infiltrating lymphocytes, enabling the immune system to recognize and eliminate malignant cells more effectively.

The therapeutic rationale for PD-1 blockade is well established across multiple solid tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer, melanoma, breast, head/neck, and prostate tumors. Zimberelimab has been developed with particular interest in combination strategies, pairing PD-1 inhibition with agents that target orthogonal immune checkpoint axes to achieve deeper and more durable antitumor responses than monotherapy alone.

Focus of Latest Publications

The most direct investigation of zimberelimab in recent literature is the ARC-10 study (PMID: 41830668), a randomized phase 2 multicenter trial evaluating zimberelimab in combination with domvanalimab as a first-line treatment for patients with PD-L1-high (tumor proportion score ≥50%), stage IIIB–IV advanced NSCLC. Domvanalimab is an Fc-silent anti-TIGIT monoclonal antibody, and the rationale for this combination lies in the complementary biology of the PD-1 and TIGIT checkpoints: both receptors are co-expressed on exhausted T cells within the tumor microenvironment, and dual blockade of PD-1 (via zimberelimab) and TIGIT (via domvanalimab) was hypothesized to produce additive or synergistic immune reactivation. The Fc-silent design of domvanalimab is notable because it aims to eliminate antibody-dependent cellular cytotoxicity against effector T cells that also express TIGIT, thereby preserving the antitumor lymphocyte population that zimberelimab is intended to reinvigorate.

The broader research landscape in which zimberelimab sits is characterized by active exploration of combination immunotherapy strategies. Related publications highlight the general field's efforts to stratify patient populations most likely to benefit from immune checkpoint combinations. For instance, work on 8-gene signatures combined with mucinous phenotype assessment has been conducted to predict which patients with dMMR/MSI-H metastatic colorectal cancer benefit from the addition of anti-CTLA-4 to anti-PD-1 regimens (PMID: 41950572), illustrating the precision oncology framework within which agents like zimberelimab are being evaluated. Similarly, a phase 1 multicenter study of S095029, an NKG2A-targeting antibody, investigated its combination with an anti-PD-1 IgG1 antibody (Sym021) in advanced malignancies (PMID: 42103356), exemplifying the broader pipeline of novel checkpoint partners being explored alongside PD-1 blockade. Research into CCR8-targeting afucosylated antibodies such as CHS-114 — evaluated with anti-PD-1 agents including toripalimab — further reflects the intensifying focus on depleting intratumoral regulatory T cells to enhance PD-1 inhibitor efficacy (PMID: 41423415). Additionally, investigations into hypoxia-inducible factor-1α (HIF-1α) and related pathways have shown that targeting hypoxic tumor microenvironments can reprogram immune cell infiltration and overcome resistance to anti-PD-1 and anti-CTLA-4 therapies, achieving high complete response rates in preclinical and translational models (PMID: 41941275).

Key Publications

Jun LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial. (Clinical cancer research : an official journal of the American Association for Cancer Research, 2026, PMID 41910591): "The purpose of the study was to evaluate the safety and preliminary antitumor activity of LM-101, an anti-SIRPα antibody that blocks the CD47-SIRPα interaction, as monotherapy and in combination with rituximab or toripalimab in relapsed/refractory lymphoma and advanced head and neck cancer."
May From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer. (European journal of cancer (Oxford, England : 1990), 2026, PMID 41950572): "Here we combine gene signature and mucinous phenotype to predict the benefit from anti-CTLA-4 plus anti-PD-1."
May Targeting conserved domains of hypoxia-inducible factors for cancer therapy. (The Journal of experimental medicine, 2026, PMID 41941275): "...and overcome resistance to anti-CTLA-4 or anti-PD-1 immunotherapy, with an aggregate complete response rate of over 50%, through reprogramming of the tumor immune cell microenvironment."
May CHS-114: An Afucosylated Anti-CCR8 Monoclonal Antibody that Selectively Depletes Intratumoral Treg Cells and Induces Antitumor Immune Responses. (Molecular cancer therapeutics, 2026, PMID 41423415): "Based on the promising preclinical data, we are evaluating CHS-114 in clinical trials as an investigational agent for the treatment of solid tumors with and without the anti-PD-1 antibody toripalimab (NCT05635643 and NCT06657144)."
May Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. (Journal for immunotherapy of cancer, 2026, PMID 42103356): "Sym021 is an anti-programmed cell death protein 1 (PD-1) IgG1 antibody."
May Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1. (Lung cancer (Amsterdam, Netherlands), 2026, PMID 41830668): "We investigated first-line domvanalimab (Fc-silent anti-TIGIT) plus zimberelimab (anti-PD-1) in PD-L1-high (≥50%), stage IIIB-IV NSCLC."